Table 1

Summary of the current literature published regarding the use of recombinant activated factor VII in trauma

Ref. (year)
Patients (n)
Type of study
Type of patients
Dose (μg/kg)
Reported reduction in transfusion requirements
Mortality (deaths; n)
Thrombotic complications

[13] (1999)
1
Case report
Penetrating
60, 60
100%
0
None
[12] (2001)
7
Case series
Blunt and penetrating
120–212
100%
3
None
[14] (2002)
1
Case report
Penetrating
90
100%
1
None
[21] (2002)
19
Case series
Blunt and penetrating
129
78%
6
1 DVT
[22] (2002)
18
Case series
Blunt and penetrating
40
83%
5
1 IAT
[17] (2003)
5
Case series
Blunt and penetrating
80–144
60%
2
None
[19] (2003)
21
Case series
Multi-trauma and surgical
30–180
86%
5
None
[20] (2004)
29
Retrospective matched case series
Blunt and penetrating
40
100%
11
None
[32] (2004)
24
Retrospective chart review
Blunt and penetrating
?
100%
9
None
[18] (2004)
81
Retrospective cohort
Blunt and penetrating
48–148
80%
47
None
Unpublished (2004)
277
Prospective phase II
Blunt and penetrating
200, 100, 100
Decreased
69
None

DVT, deep vein thrombosis; IAT, iliac artery thrombosis.

Mohr et al. Critical Care 2005 9(Suppl 5):S37   doi:10.1186/cc3784